These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9697393)

  • 1. [Use of transrectal ultrasonography in prostate pathology: determination and clinical usefulness of the prostate transition zone].
    Zlotta AR; Schulman CC
    Rev Med Brux; 1998 Jun; 19(3):119-23. PubMed ID: 9697393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
    Marks LS; Partin AW; Gormley GJ; Dorey FJ; Shery ED; Garris JB; Subong EN; Stoner E; deKernion JB
    J Urol; 1997 Jun; 157(6):2171-8. PubMed ID: 9146609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].
    MMW Fortschr Med; 2003 Feb; 145(9):54. PubMed ID: 12666533
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction.
    Zlotta AR; Djavan B; Marberger M; Schulman CC
    J Urol; 1997 Apr; 157(4):1315-21. PubMed ID: 9120930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen and transition zone index - powerful predictors for acute urinary retention in men with benign prostatic hyperplasia.
    Milonas D; Trumbeckas D
    Medicina (Kaunas); 2003; 39(11):1071-7. PubMed ID: 14646460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PSA values before and after finasteride treatment in patients with benign prostatic hypertrophy].
    Trinchieri A; Dell'Orto P
    Arch Ital Urol Androl; 1995 Feb; 67(1):33-5. PubMed ID: 7538385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen levels and density in the internal and external glands of the prostate in benign prostatic hyperplasia patients with normal or gray-zone PSA levels.
    Zuo W; Hiraoka Y
    Urol Int; 2003; 71(2):154-9. PubMed ID: 12890952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benign hyperplastic nodules that originate in the peripheral zone of the prostate gland.
    Oyen RH; Van de Voorde WM; Van Poppel HP; Brys PP; Ameye FE; Franssens YM; Baert AL; Baert LV
    Radiology; 1993 Dec; 189(3):707-11. PubMed ID: 7694310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy.
    Kirschenbaum A; Pacheco E; Schuval BJ; Levine AC
    World J Urol; 1996; 14(6):360-2. PubMed ID: 8986036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in serum prostate-specific antigen following prostatectomy in patients with benign prostate hyperplasia.
    Furuya Y; Akakura K; Tobe T; Ichikawa T; Igarashi T; Ito H
    Int J Urol; 2000 Dec; 7(12):447-51. PubMed ID: 11168683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Circulating prostatic-specific antigen in benign hypertrophy and localized prostate cancer: can PSA be considered a screening examination for localized cancer?].
    Perrin P; Francois O; Maquet JH; Bringeon G; Duteil P; Devonec M
    Prog Urol; 1991 Jun; 1(3):419-31. PubMed ID: 1726943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS; Roehrborn CG; Wolford E; Wilson TH
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated prostate volume determination with ultrasonographic imaging.
    Aarnink RG; Huynen AL; Giesen RJ; de la Rosette JJ; Debruyne FM; Wijkstra H
    J Urol; 1995 May; 153(5):1549-54. PubMed ID: 7536265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ultrasonography of the prostate].
    Fehr JL; Knönagel H
    Ther Umsch; 1992 Jan; 49(1):37-43. PubMed ID: 1371021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of men on finasteride.
    Gormley GJ
    Semin Urol Oncol; 1996 Aug; 14(3):139-44. PubMed ID: 8865475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
    Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
    Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of finasteride on prostate specific antigen: review of available data.
    Guess HA; Gormley GJ; Stoner E; Oesterling JE
    J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transrectal ultrasonography of BPH.
    Kaye KW
    Contemp Urol; 1991 Aug; 3(8):34-6; 41-50. PubMed ID: 10150974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.